Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash & Current Investments (2016 - 2025)

Guided Therapeutics' Cash & Current Investments history spans 16 years, with the latest figure at $63000.0 for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 83.76% to $63000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $63000.0, a 83.76% decrease, with the full-year FY2025 number at $63000.0, down 83.76% from a year prior.
  • Cash & Current Investments hit $63000.0 in Q4 2025 for Guided Therapeutics, down from $87000.0 in the prior quarter.
  • Over the last five years, Cash & Current Investments for GTHP hit a ceiling of $2.7 million in Q3 2022 and a floor of $63000.0 in Q4 2025.
  • Historically, Cash & Current Investments has averaged $790150.0 across 5 years, with a median of $566000.0 in 2021.
  • Biggest five-year swings in Cash & Current Investments: surged 5838.1% in 2021 and later plummeted 83.76% in 2025.
  • Tracing GTHP's Cash & Current Investments over 5 years: stood at $643000.0 in 2021, then soared by 259.72% to $2.3 million in 2022, then plummeted by 74.45% to $591000.0 in 2023, then tumbled by 34.35% to $388000.0 in 2024, then plummeted by 83.76% to $63000.0 in 2025.
  • Business Quant data shows Cash & Current Investments for GTHP at $63000.0 in Q4 2025, $87000.0 in Q3 2025, and $185000.0 in Q2 2025.